title: SNPs and taxane toxicity in breast cancer patients.
abstract: OBJECTIVE
  In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed.
  
  
  METHODS
  Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel).
  
  
  RESULTS
  Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p≤0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p≤0.01).
  
  
  CONCLUSIONS
  Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cancer patients treated with chemotherapy schemes not containing platinum. These findings could lead to better treatment selection for breast cancer patients.
authors.affiliation: Pharmacogenetics Unit, Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors.forename: Virginia
authors.initials: V
authors.lastname: Bosó
authors.forename: María José
authors.initials: MJ
authors.lastname: Herrero
authors.forename: Ana
authors.initials: A
authors.lastname: Santaballa
authors.forename: Laura
authors.initials: L
authors.lastname: Palomar
authors.forename: Juan E
authors.initials: JE
authors.lastname: Megias
authors.forename: Helena
authors.initials: H
authors.lastname: de la Cueva
authors.forename: Luis
authors.initials: L
authors.lastname: Rojas
authors.forename: María Remedios
authors.initials: MR
authors.lastname: Marqués
authors.forename: José Luis
authors.initials: JL
authors.lastname: Poveda
authors.forename: Joaquin
authors.initials: J
authors.lastname: Montalar
authors.forename: Salvador F
authors.initials: SF
authors.lastname: Aliño
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D000077143:Docetaxel; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D001952:Bridged-Ring Compounds; D004268:DNA-Binding Proteins; D043823:Taxoids; D000077143:Docetaxel; C080625:taxane; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; C071447:ERCC1 protein, human; D004720:Endonucleases; D017239:Paclitaxel
keywords: breast neoplasms; drug-related adverse reactions; genetic polymorphism; pharmacogenetics; taxoids